deinove (ALDEI:Paris Stock Exchange)

Last €10.66 EUR

Change Today -0.31 / -2.83%

Volume 2.2K

ALDEI On Other Exchanges

Symbol

Exchange

DNOVF:US

ALDEI:FP

5D8:GR

As of 11:35 AM 05/23/13 All times are local (Market data is delayed by at least 15 minutes).

deinove (ALDEI) Snapshot

Open €10.70		Previous Close €10.97
Day High €10.90		Day Low €10.65
52 Week High 03/15/13 - €13.80		52 Week Low 07/26/12 - €6.50
Market Cap 52.2M		Average Volume 10 Days 3.9K
EPS TTM --		Shares Outstanding 4.9M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

ALDEI:FP Historical Stock Quote
ALDEI:FP Advanced Stock Chart

Related News

No related news articles were found.

deinove (ALDEI) Related Businessweek News

No Related Businessweek News Found

deinove (ALDEI) Details

Deinove SA, a green technology company, engages in developing microbiological technologies for the biomass conversion, the production of biofuels and other compounds of industrial or pharmaceutical value, and green chemistry sectors. It specializes in the development of deinococcus bacteria for the production of bioethanol and green chemistry. The company was founded in 2006 and is headquartered in Paris, France.

Detailed ALDEI:FP Company Description...

www.deinove.com

30 Employees
Last Reported Date: 03/22/13

Founded in 2006

deinove (ALDEI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

deinove (ALDEI) Key Developments

Deinove SA Creates a Subsidiary for its Antibiotics Program

Mar 21 13

Deinove SA announced that the Board of Directors has decided to accelerate the development of the company's antibiotics program by establishing a subsidiary, DEINOBIOTICS, that incorporates the expertise and resources to meet its ambitions in this field. The Holding Incubator Green Chemistry has invested EUR 0.5 million and is the majority shareholder of DEINOBIOTICS with a 51% holding. The capital injection, along with the state aid already allocated, will fund DEINOBIOTICS until a first drug candidate has been identified and value created for DEINOVE.

Deinove SA Reports Earnings Results for the Year Ended December 31, 2012

Mar 21 13

Deinove SA reported earnings results for the year ended December 31, 2012. For the year, the company reported total operating income was €668,000 compared to €637,000 a year ago. Operating loss was €3,850,000 compared to €3,991,000 a year ago. Current pretax loss was €3,426,000 compared to €3,946,000 a year ago. Loss for the year was €1,979,000 compared to €3,277,000 a year ago.

Deinove SA, Annual General Meeting, May 13, 2013

Feb 7 13

Deinove SA, Annual General Meeting, May 13, 2013.